Encukalner
Bipolar Depression
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Xenon Pharmaceuticals Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07217860CT.gov An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) | — | Enrolling By Invitation | — | — | — |
NCT07172516CT.gov A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Bipolar Depression
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Encukalner (this asset) | Xenon Pharmaceuticals Inc. | P3 | B · 57 |
| Lurasidone | NeuroRx, Inc. | P4 | A |
| Lithium, Elemental | Dr. Inge Winter | P4 | BBB |
| Quetiapine | Dr. Inge Winter | P4 | BBB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Joshua Rosenblat | P4 | BBB |
| Lamotrigine | Stony Brook University | P4 | BBB |
| Escitalopram | Dr. Inge Winter | P4 | BBB |
| Nrx-101 | NeuroRx, Inc. | P3 | BBB |
| Valproic Acid | Ewha Womans University | P4 | BB |
+42 more in the Bipolar Depression cohort
Other indications for Encukalner
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Focal Epilepsy | — | P3 | BB · 67 |
| Epilepsy With Generalized Tonic-Clonic Seizures | — | P3 | B · 60 |
| Bipolar I Disorder | — | P3 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Encukalner in Bipolar Depression. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/encukalner-bipolar-depression
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →